CL2008003363A1 - Uso de 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina y sus sales farmaceuticamente aceptables para tratar depresion severa, ansiedad, abuso o dolor cronico, en pacientes que han recibido medicacion con anterioridad y que han abandonado o reducido a eventos adversos relacionados con el sueño o la actividad sexual. - Google Patents

Uso de 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina y sus sales farmaceuticamente aceptables para tratar depresion severa, ansiedad, abuso o dolor cronico, en pacientes que han recibido medicacion con anterioridad y que han abandonado o reducido a eventos adversos relacionados con el sueño o la actividad sexual.

Info

Publication number
CL2008003363A1
CL2008003363A1 CL2008003363A CL2008003363A CL2008003363A1 CL 2008003363 A1 CL2008003363 A1 CL 2008003363A1 CL 2008003363 A CL2008003363 A CL 2008003363A CL 2008003363 A CL2008003363 A CL 2008003363A CL 2008003363 A1 CL2008003363 A1 CL 2008003363A1
Authority
CL
Chile
Prior art keywords
dimethylphenylsulfanyl
piperazine
phenyl
abuse
anxiety
Prior art date
Application number
CL2008003363A
Other languages
English (en)
Inventor
Nicholas Moore
Marianne Dragheim
Aneil Batra
Jin Chon
Original Assignee
H Lundbeck As
Takeda Pharmaceuticals North America Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40170671&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008003363(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck As, Takeda Pharmaceuticals North America Inc filed Critical H Lundbeck As
Publication of CL2008003363A1 publication Critical patent/CL2008003363A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Uso de 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina y sus sales para el tratamiento de trastornos del ritmo circadiano, despertares nocturnos, de madrugada, síndrome de hipopnea, depresión, trastornos compulsivos, autismo, fatiga, epilepsia, agresión en la demencia o Alzheimer, anorexia, bulimia, entre otras.
CL2008003363A 2007-11-13 2008-11-12 Uso de 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina y sus sales farmaceuticamente aceptables para tratar depresion severa, ansiedad, abuso o dolor cronico, en pacientes que han recibido medicacion con anterioridad y que han abandonado o reducido a eventos adversos relacionados con el sueño o la actividad sexual. CL2008003363A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200701607 2007-11-13
DKPA200701788 2007-12-14
DKPA200801300 2008-09-17

Publications (1)

Publication Number Publication Date
CL2008003363A1 true CL2008003363A1 (es) 2009-06-05

Family

ID=40170671

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008003363A CL2008003363A1 (es) 2007-11-13 2008-11-12 Uso de 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina y sus sales farmaceuticamente aceptables para tratar depresion severa, ansiedad, abuso o dolor cronico, en pacientes que han recibido medicacion con anterioridad y que han abandonado o reducido a eventos adversos relacionados con el sueño o la actividad sexual.

Country Status (30)

Country Link
US (5) US9278096B2 (es)
EP (3) EP2431039B1 (es)
JP (2) JP5603244B2 (es)
KR (1) KR101536023B1 (es)
CN (1) CN102014908A (es)
AR (1) AR069260A1 (es)
AT (1) ATE537829T1 (es)
AU (1) AU2008323390B2 (es)
BR (1) BRPI0820474B8 (es)
CA (1) CA2705163C (es)
CL (1) CL2008003363A1 (es)
CO (1) CO6270322A2 (es)
CY (2) CY1112646T1 (es)
DK (2) DK2219647T4 (es)
EA (1) EA027783B1 (es)
ES (2) ES2379419T5 (es)
HR (2) HRP20120144T4 (es)
HU (1) HUE029588T2 (es)
IL (1) IL205466A (es)
LT (1) LT2431039T (es)
MX (1) MX2010004688A (es)
NZ (1) NZ585247A (es)
PL (2) PL2431039T3 (es)
PT (2) PT2431039T (es)
RS (2) RS52256B2 (es)
SG (1) SG10201405001XA (es)
SI (2) SI2219647T2 (es)
TW (1) TW200932233A (es)
WO (1) WO2009062517A1 (es)
ZA (1) ZA201003350B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200932233A (en) 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
DK2470166T3 (da) 2009-08-24 2013-09-08 Lundbeck & Co As H Nye sammensætninger af 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazin
TW201212918A (en) * 2010-08-23 2012-04-01 Lundbeck & Co As H Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
EP2667715B1 (en) * 2011-01-27 2017-07-19 Neuren Pharmaceuticals Limited Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glutamic acid
US9274127B2 (en) 2011-07-21 2016-03-01 Meijo University Method for determining depression, kit for analyzing serotonin transporter, and kit for analyzing ubiquitinated serotonin transporter in blood
GEP201706739B (en) * 2012-12-13 2017-09-25 H Lundbeck As Compositions comprising vortioxetine and donepezil
JP6323979B2 (ja) * 2013-01-17 2018-05-16 学校法人 名城大学 うつ病マーカー、アッセイ方法、測定方法、うつ病薬のスクリーニング方法及びキット
CN105339361A (zh) * 2013-05-31 2016-02-17 斯洛文尼亚莱柯制药股份有限公司 用于合成1-(2-((2，4-二甲基苯基)硫代)苯基)哌嗪的新方法
EP2878596A1 (en) * 2013-11-29 2015-06-03 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)lithium intermediates
CN105828821B (zh) * 2013-12-20 2019-04-09 H.隆德贝克有限公司 具有κ活性的阿片受体拮抗剂和沃替西汀用于治疗具有忧郁特征的抑郁障碍的用途
CN103788019B (zh) * 2014-01-22 2015-10-07 苏州明锐医药科技有限公司 沃替西汀的制备方法
WO2015114395A1 (en) 2014-01-31 2015-08-06 Egis Gyógyszergyár Zrt. Process for the preparation of vortioxetine salts
EP2930171A1 (en) * 2014-04-07 2015-10-14 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2,4-dimethylphenyl)(2-iodophenyl)sulfane intermediate
CN104119298B (zh) * 2014-08-13 2016-08-24 北京蓝贝望生物医药科技股份有限公司 氢溴酸沃赛汀或氢溴酸沃替西汀
CN104119299B (zh) * 2014-08-13 2016-08-17 北京蓝贝望生物医药科技股份有限公司 沃赛汀或沃替西汀的氢溴酸盐
CN104610195B (zh) * 2015-01-30 2017-06-27 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
JO3456B1 (ar) * 2015-05-13 2020-07-05 H Lundbeck As فيروتيوكسيتين بيروجلوتامات
BR112018000841A8 (pt) * 2015-07-17 2022-11-22 Pasteur Institut Agente estimulante de receptor 5-hidroxitriptamina1b para uso como um promotor de auto-renovação e/ou diferenciação de células satélites
WO2018002115A1 (en) 2016-07-01 2018-01-04 H. Lundbeck A/S Vortioxetine dosing regimes for fast onset of antidepressant effect
WO2021198778A1 (en) 2020-04-03 2021-10-07 H. Lundbeck A/S 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine for prevention or treatment of emotional blunting
WO2023036820A1 (en) 2021-09-10 2023-03-16 H. Lundbeck A/S Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
KR20230148676A (ko) 2022-04-18 2023-10-25 영진약품 주식회사 라베프라졸 및 탄산수소나트륨을 포함하는 조성물 및 이의 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU163075A (en) * 1975-07-21 1982-05-31 Science Union & Cie Process for preparing new phenoxy derivatives
US5258387A (en) 1990-08-21 1993-11-02 Hoffmann-La Roche Inc. Tricyclic pyridone derivatives
UA81749C2 (uk) * 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
DE60219521T2 (de) * 2001-12-20 2007-08-16 H. Lundbeck A/S Aryloxyphenyl und arylsulfanylphenylderivate
JP4667366B2 (ja) 2003-04-04 2011-04-13 ハー・ルンドベック・アクチエゼルスカベット セロトニン再取り込み阻害剤としての４−（２−フェニルスルファニル−フェニル）−ピペリジン誘導体
US20060019938A1 (en) 2003-12-31 2006-01-26 Beer Tomasz M Estrogen administration for treating male cognitive dysfunction or improving male cognitive function
EP2439201B1 (en) * 2006-06-16 2013-08-07 H. Lundbeck A/S Compounds with combined sert, 5-ht3 and 5-ht1a activity
TW200848411A (en) 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
TW200932233A (en) 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
DK2470166T3 (da) 2009-08-24 2013-09-08 Lundbeck & Co As H Nye sammensætninger af 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazin

Also Published As

Publication number Publication date
US20240082239A1 (en) 2024-03-14
PL2219647T3 (pl) 2012-07-31
US20180161321A1 (en) 2018-06-14
HUE029588T2 (en) 2017-03-28
EP3115050A1 (en) 2017-01-11
US20160228430A1 (en) 2016-08-11
EP2219647B1 (en) 2011-12-21
KR101536023B1 (ko) 2015-07-10
CY1117978T1 (el) 2017-05-17
CA2705163C (en) 2013-02-12
EP2431039B1 (en) 2016-07-20
TW200932233A (en) 2009-08-01
CN102014908A (zh) 2011-04-13
HRP20161121T1 (hr) 2017-01-27
EP2431039A1 (en) 2012-03-21
DK2431039T3 (en) 2016-09-26
IL205466A (en) 2014-06-30
SI2431039T1 (sl) 2017-01-31
ES2379419T3 (es) 2012-04-25
AU2008323390A1 (en) 2009-05-22
US9278096B2 (en) 2016-03-08
RS52256B2 (sr) 2020-11-30
SI2219647T1 (sl) 2012-06-29
CA2705163A1 (en) 2009-05-22
ZA201003350B (en) 2011-08-31
JP5841636B2 (ja) 2016-01-13
RS55147B1 (sr) 2016-12-30
US20110201617A1 (en) 2011-08-18
RS52256B (en) 2012-10-31
ATE537829T1 (de) 2012-01-15
JP2011503125A (ja) 2011-01-27
ES2591110T3 (es) 2016-11-24
IL205466A0 (en) 2010-12-30
KR101536023B9 (ko) 2023-03-29
HRP20120144T1 (en) 2012-04-30
US9744166B2 (en) 2017-08-29
SG10201405001XA (en) 2014-10-30
BRPI0820474B8 (pt) 2021-05-25
EP2219647B2 (en) 2020-07-29
BRPI0820474B1 (pt) 2020-08-04
BRPI0820474A2 (pt) 2017-05-23
CY1112646T1 (el) 2016-02-10
US20210093631A1 (en) 2021-04-01
DK2219647T3 (da) 2012-03-19
NZ585247A (en) 2012-03-30
JP2014193891A (ja) 2014-10-09
KR20100099115A (ko) 2010-09-10
AR069260A1 (es) 2010-01-06
EA027783B1 (ru) 2017-09-29
ES2379419T5 (es) 2021-05-04
US11628166B2 (en) 2023-04-18
PT2219647E (pt) 2012-03-16
LT2431039T (lt) 2016-10-10
DK2219647T4 (da) 2020-09-28
EA201070598A1 (ru) 2010-10-29
CO6270322A2 (es) 2011-04-20
JP5603244B2 (ja) 2014-10-08
HRP20120144T4 (hr) 2020-11-13
SI2219647T2 (sl) 2020-11-30
EP2219647A1 (en) 2010-08-25
AU2008323390B2 (en) 2013-10-24
PL2431039T3 (pl) 2016-12-30
PT2431039T (pt) 2016-09-29
WO2009062517A1 (en) 2009-05-22
MX2010004688A (es) 2010-09-09

Similar Documents

Publication Publication Date Title
CL2008003363A1 (es) Uso de 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina y sus sales farmaceuticamente aceptables para tratar depresion severa, ansiedad, abuso o dolor cronico, en pacientes que han recibido medicacion con anterioridad y que han abandonado o reducido a eventos adversos relacionados con el sueño o la actividad sexual.
ATE454140T1 (de) Dopamin-agonisten-kombinationstherapie mit sedativa zur verbesserung der schlafqualität
MX2011013902A (es) Tratamiento de esclerosis multiple con laquinimod.
CO6450649A2 (es) Formulaciones líquidas de sales de 1-[2-(2,4-dimetilfenilsulfanil)-fenil]piperazina
AR109103A1 (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
MX2009013989A (es) Terapia en combinacion para depresion.
EP2331095A4 (en) CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF
AR060019A1 (es) Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo
EA200601449A1 (ru) Применение агомелатина для получения лекарственных средств, предназначенных для лечения нарушений сна у пациента с депрессией
PE20060257A1 (es) Composicion farmaceutica de flibanserina para el tratamiento de trastornos premestruales y otros trastornos sexuales femeninos
BRPI0414347A (pt) associação compreendendo um ligando de alfa-2-delta e um ssri e/ou snri para tratamento de depressão e distúrbios da ansiedade
Voysey et al. The treatment of sleep dysfunction in neurodegenerative disorders
RU2008150622A (ru) Лечение агонистом мелатонина
NZ582284A (en) Carbamoyl-cyclohexanes for treating acute mania
PE20051156A1 (es) Formulaciones de matriz orales que comprenden licarbazepina
PT2111868E (pt) Utilização de albumina humana terapêutica na preparação de um medicamento para o tratamento de doentes sofrendo de distúrbios cognitivos
AR052152A1 (es) Producto farmaceutico para el tratamiento preventivo y terapeutico de trastornos del sueno
CO6220958A2 (es) Formulaciones liquidas de sales de 4-[2-(4-metilfenilsulfanil)fenil]-piperazina
RU2013112890A (ru) Терапевтическое применение 1-[2-(2,4-диметилфенилсульфанил)фенил]пиперазина
ATE487480T1 (de) Perhexilin zur behandlung von chronischer herzinsuffizienz
ATE495750T1 (de) Sulfatide zur behandlung von autoimmunkrankheiten
Blaas Treating depression with cannabinoids
EA201270551A1 (ru) Лечение нейротоксичности, ассоциированной с комбинациями 5-fu или его пролекарств с ингибиторами dpd
NZ597675A (en) Medicament for the long term nsaid use
UY31499A1 (es) Nuevo uso medico de las sales de propionato 3- (2,2,2-trimetilhydrazinio) en el trtamiento de la enfermedad cardiaca isquemica